학술논문
Clinical Efficacy of Linovin Nebulizer Therapy for Nasal Allergy / 鼻アレルギーに対するリノビン・ネビュライザー療法
Document Type
Journal Article
Author
Etsuro Obata; Fumiko Iida; Hiromi Yano; Ikuo Ohno; Katsunori Fukuda; Kazuaki Ogawa; Kei Ogawa; Kenji Katsuda; Makoto Hashimoto; Masaru Ohyama; Noriko Hashimoto; Shigeru Furuta; Takumi Yanaidani; Takuo Maeyama; Yasuichi Ohhori; 前山 拓夫; 勝田 兼司; 古田 茂; 大堀 八洲一; 大山 勝; 大野 郁夫; 小川 和昭; 小川 敬; 小幡 悦朗; 柳井谷 巧; 橋本 典子; 橋本 真実; 矢野 博美; 福田 勝則; 飯田 冨美子
Source
耳鼻咽喉科臨床 / Practica Oto-Rhino-Laryngologica. 1982, 75(10):2059
Subject
Language
Japanese
ISSN
0032-6313
1884-4545
1884-4545
Abstract
Linovin, a preparation of histamine-carried human gamma globulin, was nebulized for six weeks to 102 patients with nasal allergy to evaluate its clinical efficacy. The patients were divided into four treatment groups: the first group received the medicament once a week, the second and third groups, treated with the drug twice a week and received combined therapy with or without cepharanthin respectively. The highest improvement in nasal symptoms was observed in the group treated with Linovin (1/2 vial) alone twice a week. Of the 102 patients, clinical efficacy was excellent in 28 (27.5%), good or better in 77 (75.5%) and fair or better in 96 (94.1%).In particular, more improvement was found in nasal congestion compared with other drugs reported previously. The results of the treatment suggested that the drug should be administered twice a week for at least six weeks, particularly for nasal obstruction.